<p>A chronic metabolic condition called diabetes mellitus is typified by elevated blood sugar levels brought on by ineffective insulin production and/or action. Naturally present in thyme and oregano essential oils, the phenolic monoterpenoids thymol and carvacrol have drawn interest as possibly new agents. These bioactive compounds possess antihyperglycemic, antioxidant, and anti-inflammatory activities, which make them suitable for diabetes therapeutics. Gas chromatography was utilized to separate and analyze carvacrol, thymol, and their combinations, providing data to support the regulation of glucose metabolism through key signaling pathways PI3K/AKT and AMPK, thereby enhancing insulin sensitivity and promoting glucose uptake. Their potent antioxidant properties alleviate oxidative stress, a key factor in β-cell dysfunction and insulin resistance. Moreover, their anti-inflammatory functions block the NF-κB signal to inhibit cytokine-induced insulin resistance. While preclinical studies have shown their efficacy, their therapeutic translation is hindered by challenges such as poor bioavailability, formulation challenges, and the requirement for well-designed clinical studies. Nanotechnology and novel pharmaceutical formulations can improve their bioavailability and therapeutic efficacy. Moreover, the association with standard antidiabetic drugs, especially metformin, indicates a synergistic effect, improving glucose control and minimizing drug side effects. Future research should focus on optimizing delivery systems, standardizing formulations, and conducting comprehensive clinical studies to establish carvacrol and thymol as viable adjuncts in diabetes therapy. Given their pharmacological benefits, these natural compounds present an opportunity for developing plant-based therapeutic strategies that complement conventional diabetes management and improve patient outcomes.</p> Graphical Abstract <p></p>